Effects of hormonal treatment on lipids in patients with cancer

Cancer Treatment Reviews

Volumn 35, Issue 2, 2009, Pages 175-184

  Filippatos, T D ^a   Liberopoulos, E N ^b   Pavlidis, N ^b   Elisaf, M S ^b   Mikhailidis, D P ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Anti androgens; Apolipoproteins; Aromatase inhibitors; Cholesterol; Gonadorelin analogues; High density lipoprotein cholesterol; Oestrogens; Progestogens; Somatostatin analogues; Tamoxifen; Triglycerides

Indexed keywords

ANASTROZOLE; ANTIANDROGEN; AROMATASE INHIBITOR; CHOLESTEROL; CONJUGATED ESTROGEN; DANAZOL; DIETHYLSTILBESTROL; ESTROGEN; ETHINYLESTRADIOL; EXEMESTANE; GESTAGEN; GONADORELIN DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HORMONE ANTAGONIST; LETROZOLE; LEUPRORELIN; LEVONORGESTREL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LYNESTRENOL; MEDROXYPROGESTERONE; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE ACETATE; PLACEBO; POLYESTRADIOL; POLYESTRADIOL PHOSPHATE; SOMATOSTATIN DERIVATIVE; TAMOXIFEN; TOREMIFENE; UNINDEXED DRUG;

ADJUVANT THERAPY; BREAST CANCER; CANCER HORMONE THERAPY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG MEGADOSE; DRUG RESPONSE; ENDOMETRIOSIS; ENDOMETRIUM CANCER; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; LIPID BLOOD LEVEL; OVARIECTOMY; PROGNOSIS; PROSTATE CANCER; PROSTATE SURGERY; REVIEW; RISK FACTOR; THROMBOSIS; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS, HORMONAL; CLINICAL TRIALS AS TOPIC; HUMANS; LIPIDS; LIPOPROTEINS; NEOPLASMS;

EID: 61449130443     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2008.09.007     Document Type: Review

References (111)

1. Grundy S.M., Cleeman J.I., Merz C.N., Brewer Jr. H.B., Clark L.T., Hunninghake D.B., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 44 (2004) 720-732
2. Utsumi T., Kobayashi N., and Hanada H. Recent perspectives of endocrine therapy for breast cancer. Breast Cancer 14 (2007) 194-199
3. Namiki M., Ueno S., Kitagawa Y., Konaka H., Mizokami A., Koh E., et al. Hormonal therapy. Int J Clin Oncol 12 (2007) 427-432
4. Horwich A., Parker C., and Kataja V. Prostate cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 19 Suppl. 2 (2008) ii45-ii46
5. Agardh C.D., Nilsson-Ehle P., Lundgren R., and Gustafson A. The influence of treatment with estrogens and estramustine phosphate on platelet aggregation and plasma lipoproteins in non-disseminated prostatic carcinoma. J Urol 132 (1984) 1021-1024
6. Bulusu N.V., Lewis S.B., Das S., and Clayton Jr. W.E. Serum lipid changes after estrogen therapy in prostatic carcinoma. Urology 20 (1982) 147-150
7. Schaefer E.J., Foster D.M., Zech L.A., Lindgren F.T., Brewer Jr. H.B., and Levy R.I. The effects of estrogen administration on plasma lipoprotein metabolism in premenopausal females. J Clin Endocrinol Metab 57 (1983) 262-267
8. Moorjani S., Dupont A., Labrie F., Lupien P.J., Gagne C., Brun D., et al. Changes in plasma lipoproteins during various androgen suppression therapies in men with prostatic carcinoma: effects of orchiectomy, estrogen, and combination treatment with luteinizing hormone-releasing hormone agonist and flutamide. J Clin Endocrinol Metab 66 (1988) 314-322
9. Usui S., Suzuki K., Yamanaka H., Nakano T., Nakajima K., Hara Y., et al. Estrogen treatment of prostate cancer increases triglycerides in lipoproteins as demonstrated by HPLC and immunoseparation techniques. Clin Chim Acta 317 (2002) 133-143
10. Hiraga T., Shimokawa K., Murase T., and Yokoyama M. Reduction of serum lipoprotein (a) by estrogen in men with prostatic cancer. Endocr J 40 (1993) 507-513
11. Hiraga T., Harada K., Kobayashi T., and Murase T. Reduction of serum lipoprotein(a) using estrogen in a man with familial hypercholesterolemia. JAMA 267 (1992) 2328
12. Sotanieme E.A., and Kontture M.J. Serum lipid levels and thromboembolic complications during estrogen therapy of prostatic cancer. Scand J Urol Nephrol 9 (1975) 89-93
13. Seal U.S., Doe R.P., Byar D.P., and Corle D.K. Response of serum cholesterol and triglycerides to hormone treatment and the relation of pretreatment values to mortality in patients with prostatic cancer. Cancer 38 (1976) 1095-1107
14. Wallentin L., and Varenhorst E. Changes of plasma lipid metabolism in males during estrogen treatment for prostatic carcinoma. J Clin Endocrinol Metab 47 (1978) 596-599
15. Kostapanos M.S., Milionis H.J., Filippatos T.D., Nakou E.S., Bairaktari E.T., Tselepis A.D., et al. A 12-week, prospective, open-label analysis of the effect of rosuvastatin on triglyceride-rich lipoprotein metabolism in patients with primary dyslipidemia. Clin Ther 29 (2007) 1403-1414
16. Shinkawa T., Ohfuji T., Osada Y., and Ishisawa N. Adverse effects during endocrine therapy for prostatic carcinoma with a high dose of estrogen. Urol Int 40 (1985) 103-106
17. The Coronary Drug Project Research Group. The coronary drug project. Findings leading to discontinuation of the 2.5-mg day estrogen group. JAMA 226 (1973) 652-657
18. de Voogt H.J., Smith P.H., Pavone-Macaluso M., de Pauw M., and Suciu S. Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: results from European Organization for Research on Treatment of Cancer trials 30761 and 30762. J Urol 135 (1986) 303-307
19. Grady D., Wenger N.K., Herrington D., Khan S., Furberg C., Hunninghake D., et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The heart and estrogen/progestin replacement study. Ann Intern Med 132 (2000) 689-696
20. Manson J.E., Hsia J., Johnson K.C., Rossouw J.E., Assaf A.R., Lasser N.L., et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 349 (2003) 523-534
21. Cushman M., Legault C., Barrett-Connor E., Stefanick M.L., Kessler C., Judd H.L., et al. Effect of postmenopausal hormones on inflammation-sensitive proteins: the postmenopausal estrogen/progestin interventions (PEPI) study. Circulation 100 (1999) 717-722
22. Wakatsuki A., Ikenoue N., Shinohara K., Watanabe K., and Fukaya T. Effect of lower dosage of oral conjugated equine estrogen on inflammatory markers and endothelial function in healthy postmenopausal women. Arterioscler Thromb Vasc Biol 24 (2004) 571-576
23. Ockrim J.L., Lalani E.N., Laniado M.E., Carter S.S., and Abel P.D. Transdermal estradiol therapy for advanced prostate cancer - forward to the past?. J Urol 169 (2003) 1735-1737
24. Bland L.B., Garzotto M., DeLoughery T.G., Ryan C.W., Schuff K.G., Wersinger E.M., et al. Phase II study of transdermal estradiol in androgen-independent prostate carcinoma. Cancer 103 (2005) 717-723
25. Purnell J.Q., Bland L.B., Garzotto M., Lemmon D., Wersinger E.M., Ryan C.W., et al. Effects of transdermal estrogen on levels of lipids, lipase activity, and inflammatory markers in men with prostate cancer. J Lipid Res 47 (2006) 349-355
26. Zegura B., Guzic-Salobir B., Sebestjen M., and Keber I. The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women. Menopause 13 (2006) 643-650
27. Fahraeus L., Sydsjo A., and Wallentin L. Lipoprotein changes during treatment of pelvic endometriosis with medroxyprogesterone acetate. Fertil Steril 45 (1986) 503-506
28. Gronroos M., and Lehtonen A. Effect of high dose progestin on serum lipids. Atherosclerosis 47 (1983) 101-105
29. Lehtonen A., Gronroos M., Marniemi J., Peltonen P., Mantyla M., Niskanen J., et al. Effects of high dose progestin on serum lipids and lipid metabolizing enzymes in patients with endometrial cancer. Horm Metab Res 17 (1985) 32-34
30. Silfverstolpe G., Gustafson A., Samsioe G., and Svanborg A. Lipid metabolic studies in oophorectomised women: effects on serum lipids and lipoproteins of three synthetic progestogens. Maturitas 4 (1982) 103-111
31. Crona N., Enk L., Samsioe G., Silfverstolpe G., and Skryten A. High-dose depot-medroxyprogesterone acetate (DMPA) - effects on lipid and lipoprotein metabolism. Eur J Obstet Gynecol Reprod Biol 16 (1983) 97-105
32. Teichmann A.T., Cremer P., Wieland H., Kuhn W., and Seidel D. Lipid metabolic changes during hormonal treatment of endometriosis. Maturitas 10 (1988) 27-33
33. Hofmann M., Holzer A., Brockerhoff P., and Rathgen G.H. Plasma concentrations of non-esterified fatty acids and lipids in high-dose medroxyprogesterone therapy of metastatic breast cancer. Zentralbl Gynakol 115 (1993) 495-499
34. Teichmann A.T., Wander H.E., Cremer P., Wieland H., Kuhn W., Nagel G.A., et al. Medroxyprogesterone acetate and lipid metabolic changes. Arzneimittelforschung 37 (1987) 573-577
35. Hulley S., et al., Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 280 (1998) 605-613
36. Bertelli G., Pronzato P., Amoroso D., Cusimano M.P., Conte P.F., Montagna G., et al. Adjuvant tamoxifen in primary breast cancer: influence on plasma lipids and antithrombin III levels. Breast Cancer Res Treat 12 (1988) 307-310
37. Love R.R., Wiebe D.A., Feyzi J.M., Newcomb P.A., and Chappell R.J. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment. J Natl Cancer Inst 86 (1994) 1534-1539
38. Morales M., Santana N., Soria A., Mosquera A., Ordovas J., Novoa J., et al. Effects of tamoxifen on serum lipid and apolipoprotein levels in postmenopausal patients with breast cancer. Breast Cancer Res Treat 40 (1996) 265-270
39. Kusama M., Miyauchi K., Aoyama H., Sano M., Kimura M., Mitsuyama S., et al. Effects of toremifene (TOR) and tamoxifen (TAM) on serum lipids in postmenopausal patients with breast cancer. Breast Cancer Res Treat 88 (2004) 1-8
40. Novoa F.J., Boronat M., Carrillo A., Tapia M., Diaz-Cremades J., and Chirino R. Effects of tamoxifen on lipid profile and coagulation parameters in male patients with pubertal gynecomastia. Horm Res 57 (2002) 187-191
41. Elisaf M., Bairaktari E., Nicolaides C., Fountzilas G., Tzallas C., Siamopoulos K., et al. The beneficial effect of tamoxifen on serum lipoprotein-A levels: an additional anti-atherogenic property. Anticancer Res 16 (1996) 2725-2728
42. Hozumi Y., Kawano M., Saito T., and Miyata M. Effect of tamoxifen on serum lipid metabolism. J Clin Endocrinol Metab 83 (1998) 1633-1635
43. Milionis H.J., Liberopoulos E.N., and Elisaf M.S. Tamoxifen-induced hypertriglyceridemia in association with diabetes mellitus. Diabetes Metab 27 (2001) 160-163
44. Elisaf M., Bairaktari E., and Pavlidis N. The influence of tamoxifen on serum triglycerides. Breast 9 (2000) 238
45. Liu C.L., and Yang T.L. Sequential changes in serum triglyceride levels during adjuvant tamoxifen therapy in breast cancer patients and the effect of dose reduction. Breast Cancer Res Treat 79 (2003) 11-16
46. Liberopoulos E., Pavlidis N., and Elisaf M. The effect of tamoxifen therapy on serum apolipoprotein A-I level is modified by the apolipoprotein E phenotype. Clin Biochem 34 (2001) 161
47. Liberopoulos E., Karabina S.A., Tselepis A., Bairaktari E., Nicolaides C., Pavlidis N., et al. Are the effects of tamoxifen on the serum lipid profile modified by apolipoprotein E phenotypes?. Oncology 62 (2002) 115-120
48. Wiseman H. Tamoxifen as an antioxidant and cardioprotectant. Biochem Soc Symp 61 (1995) 209-219
49. Cuzick J. Aromatase inhibitors in prevention-data from the ATAC (arimidex, tamoxifen alone or in combination) trial and the design of IBIS-II (the second International Breast Cancer Intervention Study). Recent Results Cancer Res 163 (2003) 96-103
50. Bushnell C.D., and Goldstein L.B. Risk of ischemic stroke with tamoxifen treatment for breast cancer: a meta-analysis. Neurology 63 (2004) 1230-1233
51. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351 (1998) 1451-1467
52. Fisher B., Costantino J.P., Wickerham D.L., Redmond C.K., Kavanah M., Cronin W.M., et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 90 (1998) 1371-1388
53. Pritchard K.I., and Abramson B.L. Cardiovascular health and aromatase inhibitors. Drugs 66 (2006) 1727-1740
54. Elisaf M.S., Nakou K., Liamis G., and Pavlidis N.A. Tamoxifen-induced severe hypertriglyceridemia and pancreatitis. Ann Oncol 11 (2000) 1067-1069
55. Artac M., Sari R., Altunbas H., and Karayalcin U. Asymptomatic acute pancreatitis due to tamoxifen-induced severe hypertriglyceridemia in a patient with diabetes mellitus and breast cancer. J Chemother 14 (2002) 309-311
56. Hozumi Y., Kawano M., and Miyata M. Severe hypertriglyceridemia caused by tamoxifen-treatment after breast cancer surgery. Endocr J 44 (1997) 745-749
57. Athyros V.G., Giouleme O.I., Nikolaidis N.L., Vasiliadis T.V., Bouloukos V.I., Kontopoulos A.G., et al. Long-term follow-up of patients with acute hypertriglyceridemia-induced pancreatitis. J Clin Gastroenterol 34 (2002) 472-475
58. Mikhailidis D.P., Ganotakis E.S., Georgoulias V.A., Vallance D.T., and Winder A.F. Tamoxifen-induced hypertriglyceridaemia: seven case reports and suggestions for remedial action. Oncol Rep 4 (1997) 625-628
59. Alagozlu H., Cindoruk M., and Unal S. Tamoxifen-induced severe hypertriglyceridaemia and acute pancreatitis. Clin Drug Investig 26 (2006) 297-302
60. Lin H.H., Hsu C.H., and Chao Y.C. Tamoxifen-induced severe acute pancreatitis: a case report. Dig Dis Sci 49 (2004) 997-999
61. Ali S., and Coombes R.C. Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Cancer 2 (2002) 101-112
62. Buzdar A., and Howell A. Advances in aromatase inhibition: clinical efficacy and tolerability in the treatment of breast cancer. Clin Cancer Res 7 (2001) 2620-2635
63. Geisler J., Haynes B., Anker G., Dowsett M., and Lonning P.E. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol 20 (2002) 751-757
64. Howell A., Downey S., and Anderson E. New endocrine therapies for breast cancer. Eur J Cancer 32A (1996) 576-588
65. Lewis S. Do endocrine treatments for breast cancer have a negative impact on lipid profiles and cardiovascular risk in postmenopausal women?. Am Heart J 153 (2007) 182-188
66. Banerjee S., Smith I.E., Folkerd L., Iqbal J., Barker P., and Dowsett M. Comparative effects of anastrozole, tamoxifen alone and in combination on plasma lipids and bone-derived resorption during neoadjuvant therapy in the impact trial. Ann Oncol 16 (2005) 1632-1638
67. Sawada S., Sato K., Kusuhara M., Ayaori M., Yonemura A., Tamaki K., et al. Effect of anastrozole and tamoxifen on lipid metabolism in Japanese postmenopausal women with early breast cancer. Acta Oncol 44 (2005) 134-141
68. Dougherty R.H., Rohrer J.L., Hayden D., Rubin S.D., and Leder B.Z. Effect of aromatase inhibition on lipids and inflammatory markers of cardiovascular disease in elderly men with low testosterone levels. Clin Endocrinol (Oxf) 62 (2005) 228-235
69. Esteva F.J., and Hortobagyi G.N. Comparative assessment of lipid effects of endocrine therapy for breast cancer: implications for cardiovascular disease prevention in postmenopausal women. Breast 15 (2006) 301-312
70. Monnier A. Effects of adjuvant aromatase inhibitor therapy on lipid profiles. Expert Rev Anticancer Ther 6 (2006) 1653-1662
71. McCloskey E.V., Hannon R.A., Lakner G., Fraser W.D., Clack G., Miyamoto A., et al. Effects of third generation aromatase inhibitors on bone health and other safety parameters: results of an open, randomised, multi-centre study of letrozole, exemestane and anastrozole in healthy postmenopausal women. Eur J Cancer 43 (2007) 2523-2531
72. Mauras N., O'Brien K.O., Klein K.O., and Hayes V. Estrogen suppression in males: metabolic effects. J Clin Endocrinol Metab 85 (2000) 2370-2377
73. Jakesz R. The adjuvant endocrine treatment revolution: focus on anastrozole. Expert Opin Drug Metab Toxicol 2 (2006) 301-312
74. Bundred N.J. The effects of aromatase inhibitors on lipids and thrombosis. Br J Cancer 93 Suppl. 1 (2005) S23-S27
75. Heshmati H.M., Khosla S., Robins S.P., O'Fallon W.M., Melton III L.J., and Riggs B.L. Role of low levels of endogenous estrogen in regulation of bone resorption in late postmenopausal women. J Bone Miner Res 17 (2002) 172-178
76. Elisaf M.S., Bairaktari E.T., Nicolaides C., Kakaidi B., Tzallas C.S., Katsaraki A., et al. Effect of letrozole on the lipid profile in postmenopausal women with breast cancer. Eur J Cancer 37 (2001) 1510-1513
77. Thurlimann B., Keshaviah A., Coates A.S., Mouridsen H., Mauriac L., Forbes J.F., et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353 (2005) 2747-2757
78. Engan T., Krane J., Johannessen D.C., Lonning P.E., and Kvinnsland S. Plasma changes in breast cancer patients during endocrine therapy - lipid measurements and nuclear magnetic resonance (NMR) spectroscopy. Breast Cancer Res Treat 36 (1995) 287-297
79. Atalay G., Dirix L., Biganzoli L., Beex L., Nooij M., Cameron D., et al. The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, 'randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients'. Ann Oncol 15 (2004) 211-217
80. Lonning P.E., Geisler J., Krag L.E., Erikstein B., Bremnes Y., Hagen A.I., et al. Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol 23 (2005) 5126-5137
81. Markopoulos C., Chrissochou M., Michailidou A., Tzoracoleftherakis E., Xepapadakis G., Papadiamantis J., et al. Effect of exemestane on the lipidemic profile of post-menopausal operable breast cancer patients following 5-7 years of adjuvant tamoxifen: preliminary results of the ATENA substudy. Anticancer Drugs 16 (2005) 879-883
82. Markopoulos C., Polychronis A., Zobolas V., Xepapadakis G., Papadiamantis J., Koukouras D., et al. The effect of exemestane on the lipidemic profile of postmenopausal early breast cancer patients: preliminary results of the TEAM Greek sub-study. Breast Cancer Res Treat 93 (2005) 61-66
83. Joensuu H., Holli K., Oksanen H., and Valavaara R. Serum lipid levels during and after adjuvant toremifene or tamoxifen therapy for breast cancer. Breast Cancer Res Treat 63 (2000) 225-234
84. Howell A., Cuzick J., Baum M., Buzdar A., Dowsett M., Forbes J.F., et al. Results of the ATAC (arimidex, tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365 (2005) 60-62
85. Baum M., Budzar A.U., Cuzick J., Forbes J., Houghton J.H., Klijn J.G., et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359 (2002) 2131-2139
86. Mansel R., Locker G., Fallowfield L., Benedict A., and Jones D. Cost-effectiveness analysis of anastrozole vs tamoxifen in adjuvant therapy for early stage breast cancer in the United Kingdom: the 5-year completed treatment analysis of the ATAC ('arimidex', tamoxifen alone or in combination) trial. Br J Cancer 97 (2007) 152-161
87. Baum M., Buzdar A., Cuzick J., Forbes J., Houghton J., Howell A., et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (arimidex, tamoxifen alone or in combination) trial efficacy and safety update analyses. Cancer 98 (2003) 1802-1810
88. Bonneterre J., Thurlimann B., Robertson J.F., Krzakowski M., Mauriac L., Koralewski P., et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 18 (2000) 3748-3757
89. Nabholtz J.M., et al., Arimidex Study Group. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. J Clin Oncol 18 (2000) 3758-3767
90. Mouridsen H., Gershanovich M., Sun Y., Perez-Carrion R., Boni C., Monnier A., et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 19 (2001) 2596-2606
91. Mouridsen H., Keshaviah A., Coates A.S., Rabaglio M., Castiglione-Gertsch M., Sun Z., et al. Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial. J Clin Oncol 25 (2007) 5715-5722
92. Coombes R.C., Hall E., Gibson L.J., Paridaens R., Jassem J., Delozier T., et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350 (2004) 1081-1092
93. Jakesz R., Jonat W., Gnant M., Mittlboeck M., Greil R., Tausch C., et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366 (2005) 455-462
94. Goss P.E., Ingle J.N., Martino S., Robert N.J., Muss H.B., Piccart M.J., et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349 (2003) 1793-1802
95. Goldberg R.B., Rabin D., Alexander A.N., Doelle G.C., and Getz G.S. Suppression of plasma testosterone leads to an increase in serum total and high density lipoprotein cholesterol and apoproteins A-I and B. J Clin Endocrinol Metab 60 (1985) 203-207
96. Yannucci J., Manola J., Garnick M.B., Bhat G., and Bubley G.J. The effect of androgen deprivation therapy on fasting serum lipid and glucose parameters. J Urol 176 (2006) 520-525
97. Smith M.R., Lee H., McGovern F., Fallon M.A., Goode M., Zietman A.L., et al. Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome. Cancer 112 (2008) 2188-2194
98. Palomba S., Affinito P., Tommaselli G.A., and Nappi C. A clinical trial of the effects of tibolone administered with gonadotropin-releasing hormone analogues for the treatment of uterine leiomyomata. Fertil Steril 70 (1998) 111-118
99. Palomba S., Russo T., Orio Jr. F., Sammartino A., Sbano F.M., Nappi C., et al. Lipid, glucose and homocysteine metabolism in women treated with a GnRH agonist with or without raloxifene. Hum Reprod 19 (2004) 415-421
100. Denti L., Pasolini G., Cortellini P., Ferretti S., Sanfelici L., Ablondi F., et al. Effects of androgen suppression by gonadotropin-releasing hormone agonist and flutamide on lipid metabolism in men with prostate cancer: focus on lipoprotein(a). Clin Chem 42 (1996) 1176-1181
101. Wallentin L., and Varenhorst E. Plasma lipoproteins during treatment with cyproterone acetate in men with prostatic carcinoma. J Clin Endocrinol Metab 51 (1980) 1118-1122
102. Chen K.C., Peng C.C., Hsieh H.M., Peng C.H., Hsieh C.L., Huang C.N., et al. Antiandrogenic therapy can cause coronary arterial disease. Int J Urol 12 (2005) 886-891
103. Arosio M., et al., Italian Multicenter Octreotide Study Group. LDL physical properties, lipoprotein and Lp(a) levels in acromegalic patients. Effects of octreotide therapy. Atherosclerosis 151 (2000) 551-557
104. Gazi I.F., Tsimihodimos V., Tselepis A.D., Elisaf M., and Mikhailidis D.P. Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles. Expert Opin Biol Ther 7 (2007) 53-72
105. Attanasio R., Baldelli R., Pivonello R., Grottoli S., Bocca L., Gasco V., et al. Lanreotide 60 mg, a new long-acting formulation: effectiveness in the chronic treatment of acromegaly. J Clin Endocrinol Metab 88 (2003) 5258-5265
106. Colao A., Marzullo P., and Lombardi G. Effect of a six-month treatment with lanreotide on cardiovascular risk factors and arterial intima-media thickness in patients with acromegaly. Eur J Endocrinol 146 (2002) 303-309
107. Colao A., Spinelli L., Cuocolo A., Spiezia S., Pivonello R., di Somma C., et al. Cardiovascular consequences of early-onset growth hormone excess. J Clin Endocrinol Metab 87 (2002) 3097-3104
108. Lam K.S., Pang R.W., Janus E.D., Kung A.W., and Wang C.C. Serum apolipoprotein(a) correlates with growth hormone levels in Chinese patients with acromegaly. Atherosclerosis 104 (1993) 183-188
109. Tan K.C., Pang R.W., Tiu S.C., and Lam K.S. Effects of treatment with sandostatin LAR on small dense LDL and remnant-like lipoproteins in patients with acromegaly. Clin Endocrinol (Oxf) 59 (2003) 558-564
110. Executive S. Ummary of the third report of The National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 285 (2001) 2486-2497
111. Cuppone F., Bria E., Verma S., Pritchard K.I., Gandhi S., Carlini P., et al. Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer? Meta-analysis of randomized trials. Cancer 112 (2008) 260-267